Comparison of postvaccinal milk drop in dairy cattle vaccinated with one of two different commercial vaccines.

Several veterinarians and dairy producers elect to vaccinate dairy herds with killed combination products in the fall or spring. Postvaccinal milk drop has been reported following the use of some killed vaccines, making it important to identify vaccines that can cause milk drop and evaluate the magnitude of postvaccinal milk drop. This study compared the pre- and postvaccinal milk production levels of dairy cows vaccinated with two commercial vaccines or injected with a saline placebo. Dairy cows receiving vaccine C (Cattlemaster Gold FP5; Pfizer Animal Health, Montreal, Canada) experienced a statistically significant difference in mean postvaccinal milk drop (-1.83 kg/cow/day) compared with cows receiving vaccine T (Triangle 4+Type 2 BVD, Wyeth Animal Health, Guelph, Ontario, Canada; -0.63 kg/cow/day) or saline (-0.02 kg/cow/day).

Effect of porcine circovirus type 2 (PCV2) vaccination on porcine reproductive and respiratory syndrome virus (PRRSV) and PCV2 coinfection.

The objectives were to determine if PCV2 vaccination is effective in reducing disease and lesions associated with PRRSV and PCV2 coinfection and if there is a difference between intradermal (ID) and intramuscular (IM) route of PCV2 vaccination. Seventy-four, 21-day-old pigs were randomly allocated into one of six groups. On day 0, pigs were vaccinated with 2ml Suvaxyn PCV2 One Dose (Fort Dodge Animal Health, Inc.) by intramuscular (VAC-M-COINF) or intradermal (VAC-D-COINF) routes. On day 28, pigs were either singularly (PRRSV-only, PCV2-only) or coinfected (COINF) with PRRSV and PCV2. All pigs in all groups were necropsied on day 42. All vaccinated pigs seroconverted (IgM, IgG, and neutralizing antibodies) to PCV2 between 14 and 28 days post-vaccination. After challenge, all groups inoculated with PRRSV had reduced average daily gain compared to CONTROLS and PCV2-only (P<0.001). COINF pigs had significantly (P<0.05) reduced anti-PCV2-IgG antibody levels and neutralizing antibody levels compared to both vaccinated groups. COINF pigs had more severe lung lesions compared to VAC-M-COINF (P<0.05). COINF pigs had higher amounts of PCV2 DNA in serum samples and feces (P<0.05) and increased amounts of PCV2 in lymphoid tissues (P<0.05) compared to both vaccinated groups. In summary, PCV2 vaccination was effective at inducing a neutralizing antibody response and significantly reducing PCV2-associated lesions and PCV2 viremia in pigs coinfected with PCV2 and PRRSV. Differences between intradermal and intramuscular routes of vaccine administration were not observed.

Influence of maternal antibodies on efficacy of porcine circovirus type 2 (PCV2) vaccination to protect pigs from experimental infection with PCV2.

Due to the ubiquitous nature of porcine circovirus type 2 (PCV2) in the pig population and the increasing use of PCV2 vaccines in breeding herds, the majority of dams have been exposed to field PCV2 or PCV2 vaccines, resulting in piglets with varied levels of passively acquired PCV2 maternal antibodies. The objective of the current research was to investigate the influence of passively acquired anti-PCV2 antibodies on PCV2 vaccine efficacy. Sixty 26-day-old pigs were divided into four groups: vaccinated pigs with no maternal PCV2 antibodies at the time of vaccination (VAC-NEG; n = 9), vaccinated pigs with maternal PCV2 antibodies at the time of vaccination (VAC-POS; n = 21), nonvaccinated pigs with no maternal antibodies at the time of challenge (NVAC-CNEG; n = 15), and nonvaccinated pigs with maternal antibodies at the time of challenge (NVAC-CPOS; n = 15). Vaccinations and challenges were performed on trial days 0 and 28, respectively, according to group designation. The pigs were monitored for clinical signs of disease daily and weighed weekly, and blood was collected weekly. All pigs were necropsied on trial day 49, and tissues were evaluated for macroscopic and microscopic lesions. Serum was evaluated using PCV2 immunoglobulin G (IgG) and PCV2 IgM enzyme-linked immunosorbent assays, quantitative PCV2 PCR, and a serum PCV2 neutralizing antibody test. In comparison to NVAC-CPOS pigs, VAC-POS animals had significantly (P < 0.01) less severe microscopic PCV2-associated lymphoid lesions and significantly (P < 0.04) reduced PCV2 genomic copies in serum following PCV2 challenge. These results indicate that vaccination with Suvaxyn PCV2 One Dose reduces viremia and prevents microscopic lesions associated with PCV2 in the presence of maternal antibodies.

Evaluation of a strategic deworming program in dairy heifers in Quebec based on the use of moxidectin, an endectocide with a long persistency.

Two different deworming strategies based on the use of moxidectin, a broad spectrum endectocide with persistency against Ostertagia ostertagi, were evaluated in grazing dairy heifers. Eighty-four heifers unexposed to parasitic infection were randomly allocated to 3 different groups: untreated (Group 1), treated at 3 and 10 weeks after turnout with 0.5 mg/kg/body weight (BW) of topical moxidectin (Group 2), or treated at turnout and 10 weeks later with 0.5 mg/kg/BW of topical moxidectin (Group 3). The heifers were turned out on June 6 (Day 0) to a naturally contaminated pasture divided into 3 sections by an electrical fence. Each group of heifers was put on a different section of pasture. The trial ended when they were housed on October 29 (Day 143). The results of this experiment confirmed the beneficial effect of 2 strategic treatments with moxidectin pour-on under field conditions in Quebec. The parasitological parameters showed a statistical difference in terms of mean fecal egg counts between treated and control groups (ANOVA, P < or = 0.006). After turnout, pasture larval counts were consistently higher for Group 1 compared with counts for Group 2 or 3. All heifer groups gained weight during the trial period, but the weight gain profile of both treated groups was significantly higher than that of the untreated controls (ANOVA, P < 0.03). During the trial period, Group 2 and Group 3 gained 77.7 kg BW and 73.2 kg BW, respectively, while Group 1 gained only 57.9 kg BW, despite the fact that heifers of Group 1 received a greater quantity of supplementary feed while on pasture.